Mortality associated with heart failure with preserved vs. reduced ejection fraction in a prospective international multi-ethnic cohort study

Owan, 2006, Trends in prevalence and outcome of heart failure with preserved ejection fraction, N Engl J Med, 355, 251, 10.1056/NEJMoa052256

Bhatia, 2006, Outcome of heart failure with preserved ejection fraction in a population-based study, N Engl J Med, 355, 260, 10.1056/NEJMoa051530

Gerber, 2013, Contemporary trends in heart failure with reduced and preserved ejection fraction after myocardial infarction: a community study, Am J Epidemiol, 178, 1272, 10.1093/aje/kwt109

MAGGIC Collaborative Group, 2012, The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis, Eur Heart J, 33, 1750, 10.1093/eurheartj/ehr254

Chan, 2013, How do patients with heart failure with preserved ejection fraction die?, Eur J Heart Fail, 15, 604, 10.1093/eurjhf/hft062

Cleland, 2007, Prognosis in heart failure with a normal ejection fraction, N Engl J Med, 357, 829, 10.1056/NEJMc076179

Poppe, 2013, Known and missing left ventricular ejection fraction and survival in patients with heart failure: a MAGGIC meta-analysis report, Eur J Heart Fail, 15, 1220, 10.1093/eurjhf/hft101

Santhanakrishnan, 2013, The Singapore Heart Failure Outcomes and Phenotypes (SHOP) study and Prospective Evaluation of Outcome in Patients with Heart Failure with Preserved Left Ventricular Ejection Fraction (PEOPLE) study: rationale and design, J Card Fail, 19, 156, 10.1016/j.cardfail.2013.01.007

McMurray, 2012, ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC, Eur Heart J, 33, 1787, 10.1093/eurheartj/ehs104

Ponikowski, 2016, 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failureThe Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC, Eur Heart J, 37, 2129, 10.1093/eurheartj/ehw128

Somaratne, 2009, The prognostic significance of heart failure with preserved left ventricular ejection fraction: a literature-based meta-analysis, Eur J Heart Fail, 11, 855, 10.1093/eurjhf/hfp103

Yusuf, 2003, Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial, Lancet, 362, 777, 10.1016/S0140-6736(03)14285-7

Massie, 2008, Irbesartan in patients with heart failure and preserved ejection fraction, N Engl J Med, 359, 2456, 10.1056/NEJMoa0805450

Kang, 2015, Prognostic value of NT-proBNP in heart failure with preserved versus reduced EF, Heart, 101, 1881, 10.1136/heartjnl-2015-307782

Januzzi, 2006, NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study, Eur Heart J, 27, 330, 10.1093/eurheartj/ehi631

van Veldhuisen, 2013, B-type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction, J Am Coll Cardiol, 61, 1498, 10.1016/j.jacc.2012.12.044

Cleland, 2012, Relationship between plasma concentrations of N-terminal pro brain natriuretic peptide and the characteristics and outcome of patients with a clinical diagnosis of diastolic heart failure: a report from the PEP-CHF study, Eur J Heart Fail, 14, 487, 10.1093/eurjhf/hfs049

Anand, 2011, Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial, Circulation, 4, 569

Fonarow, 2007, Admission B-type natriuretic peptide levels and in-hospital mortality in acute decompensated heart failure, J Am Coll Cardiol, 49, 1943, 10.1016/j.jacc.2007.02.037

Iwanaga, 2006, B-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure: comparison between systolic and diastolic heart failure, J Am Coll Cardiol, 47, 742, 10.1016/j.jacc.2005.11.030

Pitt, 2014, Spironolactone for heart failure with preserved ejection fraction, N Engl J Med, 370, 1383, 10.1056/NEJMoa1313731

Cheng, 2014, Outcomes in patients with heart failure with preserved, borderline, and reduced ejection fraction in the Medicare population, Am Heart J, 168, 721, 10.1016/j.ahj.2014.07.008

Vedin, 2017, Significance of ischemic heart disease in patients with heart failure and preserved, midrange, and reduced ejection fraction: a nationwide cohort study, Circulation, 10, e003875.

Crespo-Leiro, 2016, European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-year follow-up outcomes and differences across regions, Eur J Heart Fail, 18, 613, 10.1002/ejhf.566

Lam, 016, Regional and ethnic differences among patients with heart failure in Asia: the Asian sudden cardiac death in heart failure registry, Eur Heart J 2, 37, 3141, 10.1093/eurheartj/ehw331

Carson, 2015, The Hospitalization Burden and Post-Hospitalization Mortality Risk in Heart Failure With Preserved Ejection Fraction: Results From the I-PRESERVE Trial (Irbesartan in Heart Failure and Preserved Ejection Fraction), JACC, 3, 429

Chioncel, 2017, Clinical phenotypes and outcome of patients hospitalized for acute heart failure: the ESC Heart Failure Long-Term Registry, Eur J Heart Fail, 19, 1242, 10.1002/ejhf.890